Table 2 Top 20 therapeutic target genes overexpressed in ACP compared to normal brain tissues and a variety of CNS and peripheral malignancies
From: Identification of targets for rational pharmacological therapy in childhood craniopharyngioma
Symbol | Gene name | Average percentile | # of ACP >66th %-ile | Therapeutic agents | Fold | p-Value |
|---|---|---|---|---|---|---|
MMP12 | matrix metallopeptidase 12 | 99.4 | 15 | AZD1236 | 820 | 3.03E-49 |
SHH | sonic hedgehog homolog | 98.9 | 15 | Erismodegib, Vismodegib | 96.8 | 1.48E-48 |
IL2RB | interleukin 2 receptor, beta | 96.7 | 15 | Denileukin diftitox | 12.4 | 4.87E-23 |
LCK | lymphocyte-specific protein tyrosine kinase | 95.2 | 15 | Dasatinib, Pazopanib | 5.50 | 8.24E-16 |
EPHA2 | EPH receptor A2 | 95.1 | 15 | Dasatinib, Regorafenib | 16.6 | 6.8E-16 |
AREG | Amphiregulin | 93.9 | 15 | Cetuximab | 20.8 | 4.82E-17 |
PIK3CD | phosphoinositide-3-kinase, catalytic, delta | 93.8 | 15 | Idelalisib | 6.79 | 3.55E-10 |
IL6R | interleukin 6 receptor | 91.9 | 15 | Siltuximab | 6.13 | 7.06E-8 |
MMP9 | matrix metallopeptidase 9 | 91.6 | 15 | AZD1236 | 41.0 | 9.79E-14 |
EPCAM | epithelial cell adhesion molecule | 90.7 | 15 | Tucotuzumab celmoleukin | 87.4 | 2.01E-11 |
SRC | v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog | 89.9 | 15 | Bosutinib, Dasatinib | 2.47 | 3.71e-7 |
MUC1 | mucin 1 | 89.3 | 15 | HuHMFG1 | 6.30 | 1.27E-7 |
ERBB3 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 | 86.7 | 15 | Lapatinib | 22.8 | 4.19E-08 |
TNFSF11 | tumor necrosis factor (ligand) superfamily, member 11 | 91.7 | 14 | Denosumab | 5.17 | 4.28E-8 |
MAPK14 | mitogen-activated protein kinase 14 | 91.3 | 14 | Regorafenib | 2.65 | 2.49E-8 |
PTGS2 | prostaglandin-endoperoxide synthase 2 | 85.6 | 14 | Lenalidomide | 10.5 | 9.23E-7 |
RRAS | related RAS viral (r-ras) oncogene homolog | 85.4 | 14 | Sorafenib | 3.61 | 2.32E-5 |
PSMB1 | proteasome (prosome, macropain) subunit, beta type, 1 | 83.8 | 14 | Carfilzomib | 1.45 | 5.85E-5 |
EGFR | epidermal growth factor receptor | 83.4 | 14 | Cetuximab, Erlotinib, Gefitinib, Lapatinib, etc. | 7.57 | 5.99E-05 |
CD52 | CD52 molecule | 86.3 | 13 | Alemtuzumab | 8.85 | 4.51E-12 |